Aranidipine

Aranidipine
Clinical data
AHFS/Drugs.com	International Drug Names
Routes of; administration	Oral
ATC code	none;
Legal status
Legal status	In general: ℞ (Prescription only);
Identifiers
	IUPAC name O5-methyl O3-(2-oxopropyl);
CAS Number	86780-90-7 ;
PubChem CID	2225;
ChemSpider	2139 ;
UNII	4Y7UR6X2PO;
KEGG	D01562 ;
ChEMBL	ChEMBL2104030;
CompTox Dashboard (EPA)	DTXSID9048649 ;
Chemical and physical data
Formula	C19H20N2O7
Molar mass	388.376 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C(C(C(=C(N1)C)C(=O)OCC(=O)C)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC;
	InChI InChI=1S/C19H20N2O7/c1-10(22)9-28-19(24)16-12(3)20-11(2)15(18(23)27-4)17(16)13-7-5-6-8-14(13)21(25)26/h5-8,17,20H,9H2,1-4H3 ; Key:NCUCGYYHUFIYNU-UHFFFAOYSA-N ;
	(verify)

Aranidipine (INN, trade name Sapresta) is a calcium channel blocker. It is a dihydropyridine derivative with two active metabolites (M-1α and M-1β). It was developed by Maruko Seiyaku and has the formula methyl 2-oxopropyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate. Its main use is as a hypotensive, reducing blood pressure.^[1]

References

^ "Aranidipine". PubMed. Retrieved 23 December 2018.

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.

[1] "Aranidipine". PubMed. Retrieved 23 December 2018.

[1]